The complexity and unique characteristics of the Trypanosoma cruzi genome and the relative paucity of tools to manipulate that genome are some of the challenges in the study of parasite persistence and pathogenicity that results in Chagas disease. As the highest impact infectious disease of the Americas with up to 20 million humans and innumerable animals affected, T. cruzi is plagued by poor diagnostic tools, inadequate treatment options and no effective vaccines. New discoveries in all these areas would be greatly facilitated by improved genome editing tools for T. cruzi. We have recently applied CRISPR technology to T. cruzi and demonstrate dramatically increased gene knockout and gene insertion efficiency, providing an unparalleled opportunity for genetic analysis in this important human pathogen. In this project we will further enhance the CRISPR-Cas system in T. cruzi by improving the ability to regulate Cas9 expression, better defining the mechanisms of DNA recombination used to repair Cas9-mediated double-stranded breaks, and using this information to optimize homologous recombination in T. cruzi. Using the demonstrated multiplexing capabilities of CRISPR-Cas9, we will then assess the ability to mutate of large numbers of genes encoding trans-sialidase (ts) molecules in order to evaluate the hypothesis that the ts family of molecules serves an immune evasion function for T. cruzi. This proposal combines the novel use and further development of a powerful genetic system that we demonstrate to be highly efficient in T. cruzi, with an important biological question that up to no was not experimentally tractable. Understanding the role of large gene families in the persistence and pathology of T. cruzi is only possible if we can reduce the number of family members and observe the consequences. Completion of this work is also expected to firmly establish the CRISPR-Cas system as an indispensable tool for the study of T. cruzi.

Public Health Relevance

The protozoan parasite Trypanosoma cruzi is the agent of Chagas disease, the highest impact infectious disease of the Americas with 10-20 million humans and innumerable animals affected. The study of T. cruzi and Chagas disease has been difficult in part because of the complex genome of the parasite and the lack of good research tools to manipulate that genome and determine what makes the parasite 'tic'. In this project, we will further develop a powerful new genetic tool for mutating and altering genes and make this technology accessible to the research community. We will then utilize this system to address one of the burning questions in T. cruzi and Chagas disease, the reason why this parasite generates massive families of highly related genes in its genome.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI118733-02
Application #
9205212
Study Section
Pathogenic Eukaryotes Study Section (PTHE)
Program Officer
Joy, Deirdre A
Project Start
2016-01-15
Project End
2018-12-31
Budget Start
2017-01-01
Budget End
2018-12-31
Support Year
2
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of Georgia
Department
Public Health & Prev Medicine
Type
Organized Research Units
DUNS #
004315578
City
Athens
State
GA
Country
United States
Zip Code
30602
Soares Medeiros, Lia Carolina; South, Lilith; Peng, Duo et al. (2017) Rapid, Selection-Free, High-Efficiency Genome Editing in Protozoan Parasites Using CRISPR-Cas9 Ribonucleoproteins. MBio 8: